

NMDSG2026 Fall Meeting:

How can we improve treatment and QoL in low-risk MDS?



Venue: Grand Hotel Terminus, Bergen

<https://www.debergenske.no/bergen/hotell-overnatting/grand-hotel-terminus>

Thursday, November 19th

11:30 - 12:00	Registration
12:00 - 12:50	Lunch
12:50 - 13:00	Welcome <i>Astrid M. Olsnes, NMDSG chair</i>

Scientific and clinical session I

Chairs: Lena von Bahr, Marie Bill

13:00 – 14:00	“Use of AI in MDS prognostication and stratification” <i>Matteo G. Della Porta, Humanitas Research Hospital, Milan, Italy</i>
14:00 - 14:20	Coffee break
14:20 - 15:15	“Quality of life and use of PRO in low-risk MDS” <i>Elena Crisà, INOC – Istituto Nazionale Oncologico Candiolo, Turin, Italy</i>
15:15 - 16:00	“Treating MDS at home” <i>Lars Kjeldsen, Rigshospitalet, Copenhagen</i>
16:00 - 16:30	Coffee break (check-in possible from 15:00)

Scientific session II: Oral abstracts

Chairs: Jakob Werner Hansen, Magnus Tobiasson

16:30 - 16:45	Oral abstract 1 <i>TBA</i>
16:45 - 17:00	Oral abstract 2 <i>TBA</i>
17:00 - 17:15	Oral abstract 3 <i>TBA</i>
17:15 - 17:30	Oral abstract 4 <i>TBA</i>
17:30 - 18:30	Free time

Scientific session III: Poster session incl. drinks & snacks

Chairs: Mikko Myllymäki, Synne Torkildsen

18:30 - 19:30	<i>3-minute PitchTalk from presenters at each poster!</i>
19:30	Dinner

Scientific & Clinical session I:

Chairs: Astrid Olsnes, TBA

- | | |
|---------------|--|
| 09:00 - 09:30 | “Study proposal: use of Smart-Watches to individualise treatment in transfusion-dependent MDS”
<i>Lena von Bahr, Sahlgrenska University Hospital, Gothenburg</i> |
| 09:30 - 10:00 | “IDH1/2-driven hyperinflammation in CCUS/MDS”
<i>Niklas Landberg, Lund University Cancer Center, Lund</i> |
| 10:00 - 10:30 | “Bexmarilimab in low-risk MDS”
<i>Mikko Myllymäki, Helsinki University Hospital, Helsinki</i> |
| 10:30 - 10:45 | Coffee break (check-out by 11:00) |
| 10:45 - 11:30 | “VEX-AZA update”
<i>Markus Korsholm Kristensen, Sune Bengtsen Holm Hansen, Rigshospitalet, Copenhagen</i> |
| 11:30 - 12:00 | “NMDSG14B Part 2 – update”
<i>Magnus Tobiasson, Karolinska Institutet and Karolinska University Hospital, Stockholm</i> |
| 12:00 - 12:15 | “Clinical and biological determinants of response and resistance to azacitidine in TP53-mutated MDS”
<i>Petter Woll, Jenny Rydén, Karolinska Institutet and Karolinska University Hospital, Stockholm</i> |
| 12:15 - 13:15 | Lunch |
| 13:15 - 14:00 | “EVI 2-3-4 update”
<i>Kirsten Grønbæk, Stine Ulrik Mikkelsen, Ali Al-Mousawi, Rigshospitalet, Copenhagen</i> |
| 14:00 - 14:30 | General assembly NMDSG
<i>Members of NMDSG</i> |
| 14:30 - 15:00 | Coffee break |

Scientific & Clinical session II:

Chairs: TBA

- | | |
|---------------|--|
| 15:00 - 15:30 | “International MDS guidelines - update”
<i>Eva Hellstöm Lindberg, Karolinska Institutet and Karolinska University Hospital, Stockholm</i> |
| 15:30 - 16:00 | “Experience with Imetelstat / Luspatercept”
<i>(TBA)</i> |
| 16:00 | Coffee and farewell |